Conflicts seen on guidelines panel
The AHA/ACC panel that wrote the potentially practice-changing cholesterol guidelines issued last month included six members with ties to drugmakers that sell or are developing lipid medications, Pharmalot reported. Each disclosed they worked as a consultant and received funding for personal research.
Among the 10 expert reviewers, half listed consulting relationships with such companies cited as Merck, Amgen, AstraZeneca, Pfizer, Amarin, Roche and Abbott Laboratories, whose cholesterol pills are sold by AbbVie. An AHA spokeswoman responded that none of the ACC/AHA expert reviewers had “relevant” relationships with industry.